VEGFA and hepatocellular carcinoma: Previous studies have also showed that combination treatments comprising of vascular endothelial growth factor (VEGF)-mediated immune suppression and PD-1 inhibitors, such as pembrolizumab, are promising options in achieving better prognosis for HCC patients, especially in HBV-related HCC (3, 4).